United Therapeutics Corporation Total Liabilities
United Therapeutics Corporation total liabilities. Based on the latest financial reports, United Therapeutics Corporation (UTHR) has total liabilities worth $819.80 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See UTHR cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of United Therapeutics Corporation (1998–2025)
Total liabilities of United Therapeutics Corporation from 1998 to 2025. This chart illustrates how United Therapeutics Corporation's total liabilities have evolved over time, based on quarterly financial data. Check United Therapeutics Corporation asset resilience ratio to evaluate the company's liquid asset resilience ratio.
United Therapeutics Corporation Competitors by Total Liabilities
The table below lists competitors of United Therapeutics Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Carso S.A.B. de C.V
MX:GCARSOA1
|
Mexico | MX$95.27 Billion |
|
Banco de Chile
SN:CHILE
|
Chile | CL$49.93 Trillion |
|
Hyundai Mobis Co.,Ltd
KO:012330
|
Korea | ₩23.77 Trillion |
|
Arca Continental S.A.B. de C.V
MX:AC
|
Mexico | MX$142.29 Billion |
|
Henkel AG & Co. KGaA
XETRA:HEN
|
Germany | €15.43 Billion |
|
Amcor Plc
AU:AMC
|
Australia | AU$25.92 Billion |
|
Kuehne & Nagel
SW:KNIN
|
Switzerland | CHF9.73 Billion |
|
Equifax Inc
NYSE:EFX
|
USA | $7.26 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down United Therapeutics Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of United Therapeutics Corporation.
Liquidity & Leverage Metrics
United Therapeutics Corporation Total Liabilities Ratios Explained
United Therapeutics Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how United Therapeutics Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for United Therapeutics Corporation (1998–2025)
The table below shows the annual total liabilities of United Therapeutics Corporation from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $783.80 Million | -14.80% |
| 2024-12-31 | $920.00 Million | -22.18% |
| 2023-12-31 | $1.18 Billion | -5.26% |
| 2022-12-31 | $1.25 Billion | +3.11% |
| 2021-12-31 | $1.21 Billion | -0.79% |
| 2020-12-31 | $1.22 Billion | +7.66% |
| 2019-12-31 | $1.13 Billion | +85.01% |
| 2018-12-31 | $612.40 Million | -21.24% |
| 2017-12-31 | $777.60 Million | +67.80% |
| 2016-12-31 | $463.40 Million | -20.76% |
| 2015-12-31 | $584.80 Million | -5.50% |
| 2014-12-31 | $618.84 Million | -20.99% |
| 2013-12-31 | $783.26 Million | +47.30% |
| 2012-12-31 | $531.73 Million | -6.65% |
| 2011-12-31 | $569.59 Million | +3.99% |
| 2010-12-31 | $547.75 Million | +37.44% |
| 2009-12-31 | $398.54 Million | +9.60% |
| 2008-12-31 | $363.62 Million | +24.86% |
| 2007-12-31 | $291.23 Million | +6.31% |
| 2006-12-31 | $273.94 Million | +1579.50% |
| 2005-12-31 | $16.31 Million | +5.08% |
| 2004-12-31 | $15.52 Million | +32.25% |
| 2003-12-31 | $11.74 Million | -9.07% |
| 2002-12-31 | $12.91 Million | -17.90% |
| 2001-12-31 | $15.72 Million | -1.16% |
| 2000-12-31 | $15.91 Million | +152.50% |
| 1999-12-31 | $6.30 Million | +215.00% |
| 1998-12-31 | $2.00 Million | -- |
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil)… Read more